查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1647465

良性前列腺增生治疗市场规模、份额和成长分析（按治疗方法、类型、产品、最终用户和地区）- 产业预测 2025-2032

Benign Prostatic Hyperplasia Treatment Market Size, Share, and Growth Analysis, By Treatment (Minimal Invasive Surgery, Invasive Surgery), By Type (Drug Treatment, Surgical Treatment), By Product, By End User, By Region - Industry Forecast 2025-2032
出版日期: | 出版商: SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格
简介目录

2023 年全球良性前列腺增生治疗市场规模价值为 114.5 亿美元，预计将从 2024 年的 120.8 亿美元增长到 2032 年的 185.4 亿美元，预测期内（2025-2032 年）的复合年增长率为 5.5%。

由于几个关键因素，良性前列腺增生 (BPH) 治疗市场正在经历显着成长。人口老化导致全球 BPH 的盛行率上升，寻求治疗的患者数量也随之增加。因此，对创新、微创手术的需求日益增加，例如经尿道前列腺切除术(TURP)、雷射治疗和前列腺动脉栓塞术 (PAE)，这些手术具有恢復时间更短、併发症更少等优点。此外，透过公共卫生倡议和教育，人们对 BPH 的认识有所提高，从而提高了对该病症的认识并实现了早期诊断和治疗。此外，支持性的法律规范和有利的报销政策正在推动先进治疗方案的采用，进一步促进该领域的市场扩张。

目录

介绍

  • 调查目的
  • 研究范围
  • 定义

调查方法

  • 资讯采购
  • 资料和主要资料方法
  • 市场规模预测
  • 市场假设与限制

执行摘要

  • 全球市场展望
  • 供需趋势分析
  • 细分机会分析

市场动态及展望

  • 市场概况
  • 市场规模
  • 市场动态
    • 驱动因素和机会
    • 限制与挑战
  • 波特的分析

主要市场考察

  • 关键成功因素
  • 竞争程度
  • 主要投资机会
  • 市场生态系统
  • 市场吸引力指数（2024 年）
  • PESTEL 分析
  • 总体经济指标
  • 价值链分析
  • 定价分析

良性前列腺增生治疗市场规模（依治疗方法及复合年增长率）（2025-2032）

  • 市场概况
  • 微创手术
  • 侵入性手术

良性前列腺增生治疗市场规模（按类型和复合年增长率）（2025-2032）

  • 市场概况
  • 药物治疗
    • 阿尔法阻断剂
    • 阿夫唑嗪
    • 多沙唑嗪
    • Tamsulosin
    • 西洛多辛
    • 其他 α阻断剂
    • 5-α-还原酶抑制剂
    • Finasteride
    • 度他雄胺
    • 其他药物类别
  • 手术治疗
    • 经尿道前列腺切除术(TURP)
    • 尿道热疗法(TUMT)
    • 经尿道摄护腺针刺消融术 (TUNA)
    • 雷射治疗
    • 摄护腺支架
    • 泌尿道提升疗法
    • Rezam疗法
    • 其他手术

良性摄护腺增生治疗市场规模（依产品及复合年增长率） (2025-2032)

  • 市场概况
  • 电切镜
  • 泌尿系统雷射
  • 射频消融术
  • 电极
  • 导管
  • 摄护腺支架
  • 植入
  • 其他的

良性前列腺增生治疗市场规模（按最终用户和复合年增长率） (2025-2032)

  • 市场概况
  • 家庭医疗保健
  • 医院和诊所
  • 研究与製造

良性摄护腺增生治疗市场规模（按地区）及复合年增长率（2025-2032）

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 义大利
    • 其他欧洲国家地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲国家
  • 中东和非洲
    • 海湾合作委员会国家
    • 南非
    • 其他中东和非洲地区

竞争资讯

  • 前 5 家公司对比
  • 主要企业市场定位（2024年）
  • 主要市场参与者所采用的策略
  • 近期市场趋势
  • 公司市场占有率分析（2024 年）
  • 主要企业简介
    • 公司简介
    • 产品系列分析
    • 按细分市场分析市场份额
    • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

  • Boston Scientific Corporation（USA）
  • Pfizer Inc.（USA）
  • GlaxoSmithKline plc（UK）
  • Eli Lilly and Company（USA）
  • Abbott Laboratories（USA）
  • Astellas Pharma Inc.（Japan）
  • Sanofi SA（France）
  • Merck & Co., Inc.（USA）
  • Teleflex Incorporated（USA）
  • Olympus Corporation（Japan）
  • Coloplast Group（Denmark）
  • Asahi Kasei Corporation（Japan）
  • Allergan plc（Ireland）
  • IPG Photonics Corporation（USA）
  • Richard Wolf GmbH（Germany）
  • Biolitec AG（Austria）
  • Urologix, LLC（USA）
  • Procept BioRobotics Corporation（USA）
  • Lumenis Ltd.（Israel）
  • KARL STORZ SE & Co. KG（Germany）

结论和建议

简介目录
Product Code: SQMIG35E2045

Global Benign Prostatic Hyperplasia Treatment Market size was valued at USD 11.45 billion in 2023 and is poised to grow from USD 12.08 billion in 2024 to USD 18.54 billion by 2032, growing at a CAGR of 5.5% during the forecast period (2025-2032).

The market for Benign Prostatic Hyperplasia (BPH) treatment is experiencing significant growth due to several key factors. The rising global prevalence of BPH, driven by an aging population, is expanding the patient base seeking treatment. Consequently, there is increased demand for innovative, minimally invasive procedures like transurethral resection of the prostate (TURP), laser therapy, and prostatic artery embolization (PAE), which offer benefits such as shorter recovery times and fewer complications. Furthermore, heightened awareness of BPH through public health initiatives and education has improved symptom recognition, leading to earlier diagnoses and treatment. Moreover, supportive regulatory frameworks and favorable reimbursement policies are encouraging the adoption of advanced treatment options, further propelling market expansion in this sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Benign Prostatic Hyperplasia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Benign Prostatic Hyperplasia Treatment Market Segments Analysis

Global Benign Prostatic Hyperplasia Treatment Market is segmented by Treatment, Type, Product, End User and region. Based on Treatment, the market is segmented into Minimal Invasive Surgery and Invasive Surgery. Based on Type, the market is segmented into Drug Treatment and Surgical Treatment. Based on Product, the market is segmented into Resectoscopes, Urology Laser, Radiofrequency Ablation, Electrodes, Catheters, Prostatic Stents, Implants and Others. Based on End User, the market is segmented into Home Healthcare, Hospitals & Clinics and Research & Manufacturing. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Benign Prostatic Hyperplasia Treatment Market

The increasing awareness of benign prostatic hyperplasia (BPH) and its related symptoms is paving the way for earlier detection and diagnosis. Various stakeholders-including governments, healthcare organizations, and advocacy groups-are engaged in efforts to raise awareness through campaigns and screening initiatives focused on BPH. This proactive approach to early intervention and timely treatment not only helps men seek help sooner but also substantially drives the expansion of the BPH treatment market. As awareness grows and initiatives proliferate, a greater number of patients will be likely to pursue available treatment options, thereby enhancing market growth.

Restraints in the Global Benign Prostatic Hyperplasia Treatment Market

The global Benign Prostatic Hyperplasia (BPH) treatment market faces significant restraints due to the expiration of patents on key medications, which has led to an influx of generic versions of treatments like alpha-blockers and 5-alpha reductase inhibitors. This shift has created pricing pressures that negatively impact the revenue streams of branded products. As generic alternatives become more widely available, they offer patients more affordable treatment options, thereby altering market dynamics. Consequently, this heightened competition could hinder the growth potential of branded therapies, making it essential for companies to adapt to the evolving landscape to maintain their market positions.

Market Trends of the Global Benign Prostatic Hyperplasia Treatment Market

The Global Benign Prostatic Hyperplasia (BPH) treatment market is experiencing a marked shift toward minimally invasive procedures, reflecting a broader trend in urological care that prioritizes patient comfort and recovery. Techniques like transurethral resection of the prostate (TURP), laser ablation, and prostatic urethral lift (PUL) are gaining popularity due to their advantages over traditional surgical methods, including reduced hospital stays, quicker recovery times, and fewer postoperative complications. This movement aligns with the growing emphasis on patient-centered care and enhancing the quality of life, as well as the need to optimize healthcare costs, positioning minimally invasive treatments as a driving force in the BPH market's evolution.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis

Global Benign Prostatic Hyperplasia Treatment Market Size by Treatment & CAGR (2025-2032)

  • Market Overview
  • Minimal Invasive Surgery
  • Invasive Surgery

Global Benign Prostatic Hyperplasia Treatment Market Size by Type & CAGR (2025-2032)

  • Market Overview
  • Drug Treatment
    • Alpha Blockers
    • Alfuzosin
    • Doxazosin
    • Tamsulosin
    • Silodosin
    • Other Alpha Blockers
    • 5-Aplha Reductase Inhibitors
    • Finasteride
    • Dutasteride
    • Other Drug Classes
  • Surgical Treatment
    • Transurethral Resection of the Prostate (TURP)
    • Transurethral Microwave Thermotherapy (TUMT)
    • Transurethral Needle Ablation of the Prostate (TUNA)
    • Laser Therapy
    • Prostatic Stenting
    • UroLift Therapy
    • Rezum Therapy
    • Other Surgeries

Global Benign Prostatic Hyperplasia Treatment Market Size by Product & CAGR (2025-2032)

  • Market Overview
  • Resectoscopes
  • Urology Laser
  • Radiofrequency Ablation
  • Electrodes
  • Catheters
  • Prostatic Stents
  • Implants
  • Others

Global Benign Prostatic Hyperplasia Treatment Market Size by End User & CAGR (2025-2032)

  • Market Overview
  • Home Healthcare
  • Hospitals & Clinics
  • Research & Manufacturing

Global Benign Prostatic Hyperplasia Treatment Market Size & CAGR (2025-2032)

  • North America (Treatment, Type, Product, End User)
    • US
    • Canada
  • Europe (Treatment, Type, Product, End User)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Treatment, Type, Product, End User)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Treatment, Type, Product, End User)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Treatment, Type, Product, End User)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Boston Scientific Corporation (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Abbott Laboratories (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Astellas Pharma Inc. (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi S.A. (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teleflex Incorporated (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Olympus Corporation (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Coloplast Group (Denmark)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Asahi Kasei Corporation (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Allergan plc (Ireland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • IPG Photonics Corporation (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Richard Wolf GmbH (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biolitec AG (Austria)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Urologix, LLC (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Procept BioRobotics Corporation (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Lumenis Ltd. (Israel)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • KARL STORZ SE & Co. KG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations